D Molecular Therapeutics (NASDAQ:FDMT) achieves FDA RMAT status for 4D-150 as a diabetic macular edema treatment, backed by ...

A single intravitreal injection of UBX1325 (foselutoclax) was shown to be safe in patients with diabetic macular edema. The ...

D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and ...

New treatments for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) enhance patient care with gene therapies and new mechanisms of action on the horizon, explained ...

New research reveals UBX1325's potential to significantly improve vision in diabetic macular edema patients, offering hope ...

The FDA has accepted for Priority Review the sBLA for aflibercept injection 8mg for the treatment of macular edema following RVO and for monthly dosing in approved indications.

Epiretinal membrane removal leads to significant anatomical changes that are more pronounced in eyes without glaucoma.

Of all the focal lengths in photography, the 50mm has always been the one that felt like home to me. There’s something deeply intuitive about it, a way it renders the world that feels close to how I ...

UBX1325 is a novel BCL-xL inhibitor designed to eliminate senescent cells in diabetic retinal blood vessels, while leaving healthy ones intact.